Abstract
To determine the safety of ceftriaxone in paediatric patients and systematically evaluate the categories and incidences of adverse drug reactions (ADRs) of ceftriaxone in paediatric patients. We performed a systematic search in Medline, PubMed, Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, International Pharmaceutical Abstracts and bibliographies of relevant articles up to December 2018 for all types of studies that assessed the safety of ceftriaxone in paediatric patients aged ≤18 years. 112 studies met the inclusion criteria involving 5717 paediatric patients who received ceftriaxone and reported 1136 ADRs. The most frequent ADRs reported in prospective studies were gastrointestinal (GI) disorders (37.4 %, 292/780), followed by hepatobiliary disorders (24.6%, 192/780). Serious ADRs leading to withdrawal or discontinuation of ceftriaxone were reported in 86 paediatric patients. Immune haemolytic anaemia (34.9%, 30/86) and biliary pseudolithiasis (26.7%, 23/86) were the two major causes. Haemolytic anaemia following intravenous ceftriaxone led to death in 11 children whose primary disease was sickle cell disease. Almost all biliary pseudolithiasis are reversible. However, the incidence was high affecting one i...Continue Reading
References
Jan 18, 1990·The New England Journal of Medicine·U B SchaadJ Wedgwood
May 1, 1995·The Journal of Pediatrics·J C BerniniG R Buchanan
Nov 4, 1994·Health Libraries Review·C Lefebvre
Feb 7, 2001·Journal of Clinical Ultrasound : JCU·A PalanduzA Somer
Dec 1, 2000·The Pediatric Infectious Disease Journal·E LeibovitzR Dagan
Dec 7, 2000·Clinical Pharmacokinetics·I Lutsar, I R Friedland
May 3, 2002·Drugs·Harriet M LambDavid P Figgitt
Jan 18, 2007·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Masoumeh MohkamMostafa Sharifian
Oct 24, 2008·International Journal of Antimicrobial Agents·Adriano ArguedasUNKNOWN Protocol 036 Study Group
Jul 24, 2010·European Journal of Epidemiology·Andreas Stang
Nov 30, 2011·Journal of Clinical Pharmacy and Therapeutics·G ShalviriK Gholami
Jun 13, 2012·Pediatric Reports·Takahisa KimataMinoru Kino
Aug 29, 2014·The Annals of Pharmacotherapy·Gal NeumanShinya Ito
Apr 16, 2016·Journal of Clinical Medicine Research·Qais AljfoutMohammad Saraireh
Apr 20, 2016·The Pediatric Infectious Disease Journal·Christopher R CannavinoSheldon L Kaplan
Jul 13, 2016·Human & Experimental Toxicology·L UstyolM Dogan
Aug 23, 2017·BMJ Open·Linan ZengMiaomiao He
Aug 24, 2017·Patient Preference and Adherence·Md Mahbubur RashidFahmida Chowdhury
Dec 29, 2017·Archives of Disease in Childhood·Godwin OligbuShamez Ladhani
Feb 14, 2018·Pediatrics·Sarah L ReevesKevin J Dombkowski
Apr 14, 2018·Evidence-based Mental Health·Orestis Efthimiou